July 28, 2026 — Abbott has initiated the Treat TR study, a post-market study of the company’s TriClip transcatheter edge-to-edge repair (TEER) system that is designed for treating tricuspid regurgitation (TR), or a leaky tricuspid valve. The first enrollment in the Treat TR study occurred at Hospital Clínic de Barcelona in Spain, led by Xavier Freixa, M.D., and his cardiac team. Treating Tricuspid RegurgitationThe tricuspid valve controls blood as it flows from the heart’s right atrium to the right ventricle. It works by clipping together leaflets – or flaps of tissue – to repair the tricuspid valve, helping restore proper blood flow. Additional real-world data evaluating the TriClip system were presented in June 2026 at the New York Valves conference.